<DOC>
	<DOCNO>NCT00048347</DOCNO>
	<brief_summary>This study evaluate safety effectiveness drug interferon-beta1a ( AVONEX ) treat ulcerative colitis examine drug 's effect immune system . People ulcerative colitis increase amount inflammatory chemical ( cytokine ) make immune cell line colon . Studies show interferon-beta may block activity cytokine . Interferon-beta1a ( AVONEX ) currently FDA-approved treat multiple sclerosis , disease involve inflammation brain spinal cord . Patients 18 year age older ulcerative colitis least 4 month may eligible study . Candidates screen review medical record , medical history physical examination , electrocardiogram ( EKG ) , blood , urine , stool test , pregnancy test woman childbearing potential . A colonoscopy also do determine disease activity extent . This test use light tube examine amount inflammation colon take tissue sample ( biopsy ) test . Before test , patient give medicine allay anxiety discomfort insert endoscope rectum . This flexible tube allow doctor see intestinal mucosa project image inner line intestine onto TV monitor . At various place intestine , small piece tissue pluck special device tip endoscope . The procedure generally last 30 minute 1 hour . Participants come NIH Clinical Center week 4 week receive injection interferon-beta , fill questionnaire , symptom check , physical examination , blood test . Patients whose colitis worsen end 4 week significant drug side effect continue receive weekly injection additional 8 week . Some patient may receive last eight injection outside NIH , patient visit Clinical Center visit every 3 4 week physical exam , symptom check blood test . After 12 injection complete , patient another colonoscopy evaluate response treatment return Clinical Center every 6 week total four visit , physical examination , symptom check blood test .</brief_summary>
	<brief_title>Interferon-beta1a ( AVONEX ) Treatment Ulcerative Colitis</brief_title>
	<detailed_description>The purpose pilot study evaluate immunologic clinical response type I interferon administered patient ulcerative colitis . Ulcerative colitis ( UC ) chronic , relapse inflammation colonic mucosa major symptom diarrhea , hematochezia , abdominal pain , accompany increase colorectal carcinoma risk . Novel approach therapy UC require burden disease great ( 500,000 prevalent case United States ) , standard medical therapy limit effectiveness toxicity , surgical therapy , albeit curative , result permanent ostomy complication-prone alternative . The rationale study base observation mucosal inflammation UC may mediate Th2 cytokine IL-4 cytokine induce along IL-4 . Type I interferons block IL-4 receptor signal up-regulating cytosolic inhibitory protein ( suppressor cytokine signal SOCS protein ) . Furthermore , two small study type I interferon effect UC show benefit oppose many study Crohn 's disease , classic Th1 inflammatory disease , show benefit type I interferon . We hypothesize type I interferon could use inhibit pro-inflammatory signal Th2 cytokine UC . This study measure immunologic clinical effect twelve week treatment type I interferon administered patient active UC . The primary outcome include document change immune parameter measure peripheral lamina propria mononuclear cell cytokine release , expression level SOCS proteins mononuclear cell , change clinical parameter use Short Clinical Colitis Activity Index endoscopic histologic score . Secondary endpoint include rate severity adverse event . Our short-term goal correlate change immune biochemical parameter accompany predict clinical response . The long-term goal study establish type I interferons effective alternative adjunctive therapy low risk profile treatment ulcerative colitis .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Age 18 year old great . 2 . Diagnosis ulcerative colitis least 4 month base endoscopic appearance radiographic distribution disease corroborate histopathology ( especially absence granuloma ) . 3 . Presence current active disease define Simple Clinical Colitis Activity Index great equal 5 ( either two measurement do Screening Phase second measurement within 50 percent value first ) may may presence one following : current corticosteroid dependence disease treatment , disease refractory corticosteroid , history intolerance treatment corticosteroid ( criterion coadministered corticosteroid dose see ) . Corticosteroiddependence define relapse ulcerative colitis within 60 day complete course corticosteroid treatment , corticosteroid tapering dos great equal 10 mg prednisone/day ( equivalent ) , within three month follow corticosteroid taper receive steroid dose great equal 10 mg prednisone/day ( equivalent ) . 4 . If currently receive medication ulcerative colitis , patient may stable regimen one combination follow drug dos duration : Corticosteroids ( less equal 25 mg Prednisone/d Prednisone equivalent ) great equal 4 week ; 5ASA/Sulfasalazine great equal 4 week ; Azathioprine/6MP/thioguanine great equal 12 week . ( Note : Patients receive azathioprine/6MP/thioguanine must stable dose medication great equal 8 week randomization ) ; Probiotics ( live bacterial dietary supplement ) great equal 4 week ; Prebiotics ( dietary supplement produce biologically active substance ) great equal 4 week . 5 . Use barrier hormonal method birth control female subject surgically sterile postmenopausal . 6 . Negative serum betahCG woman childbearing potential ( woman surgically sterile postmenopausal ) exclude early unnoticed pregnancy . 7 . Negative result stool examination culture enteric pathogen ( Salmonella , Shigella , Yersinia , Campylobacter , Vibrio , E. coli O157/H7 ) , Clostridium difficile toxin assay , enteric parasite ova ( include Giardia Cryptosporidia ) . 8 . Thyroid function test TSH level within establish normal range set Clinical Center . EXCLUSION CRITERIA : 1 . Inability meet inclusion criterion . 2 . Use following medication within specified time period prior first dose interferonbeta time study : Nonsteroidal antiinflammatory agent ( include COX2 inhibitor ) , 1 week Corticosteroids ( great 25 mg Prednisone/d Prednisone equivalent ) , Methotrexate , Cyclosporin , Tacrolimus , Thalidomide , Mycophenolate mofetil 4 week Monoclonal antibody TNF alpha Other Biologic ( cytokine , anticytokine , integrinbased therapy , instance ) 4 month Any experimental agent 1 month Concomitant use follow drug : isoniazid , iproniazid , dantrolene , ticrynafen ( tienilic acid ) , ibufenac , bromfenac , benoxaprofen , zileutan , nicotinic acid , trovafloxacin , perhexiline , dilevavol , labetalol , pemoline , felbamate , tolcapone , diclofenac , AIDS drug ( HIV+ subject exclude anyway ) , troglitozone . 3 . History colectomy , partial colectomy , current ostomy , pouchitis . 4 . Presence significant electrocardiogram abnormality include QT ( c ) great equal 0.48 sec , Mobitz type II second degree third degree atrioventricular block , leave bundle branch block right bundle branch block accompany fascicular block , change consistent acute ischemia pericarditis . 5 . Presence diagnosis Crohn 's disease , indeterminate colitis , microscopic colitis , ischemic colitis , colitis attributable infection . This determination may require use clinical , endoscopic , histologic data . 6 . Presence Cushing 's syndrome . 7 . Presence current active bowel obstruction , intestinal perforation , significant GI hemorrhage , know presence high grade stricture , history toxic megacolon , history colonic epithelium highgrade dysplasia dysplasiaassociated lesion mass resemble adenoma ( mass lesion , stricture , broadbased tumor ) . 8 . Anticipation surgery may require treat ulcerative colitis within 3 month study entry . 9 . HIV positivity sign symptoms consistent HIV infection . 10 . Acute systemic intestinal infection require antibiotic . 11 . Active hepatitis B C. 12 . Decompensated liver disease ( ChildsPugh class B C ) . 13 . Hematocrit le 30 percent Platelet count 120,000 less great 850,000 PT INR great 1.3 PTT prolong great 3 second Serum creatinine BUN great 1.5 time upper limit normal ( ULN ) ALT ( SGPT ) AST ( SGOT ) great 2 time ULN Total bilirubin great 1.25 time ULN Alkaline phosphatase great 1.5 time ULN . 14 . Pregnancy nursing ( woman ) . 15 . History cancer ( resect cutaneous basal squamous cell carcinoma situ cervical cancer ) less 5 year ' documentation diseasefree state . 16 . History myocardial infarction within last 12 month . 17 . Any condition investigator 's opinion place patient undue risk participate study . This include limited : psoriasis , thyroid disease , myasthenia gravis , lupus erythematosus , rheumatoid arthritis , Raynaud 's disease , autoimmune hepatitis , C1 esterase deficiency deficiency complement system , plasma cell dyscrasia . 18 . History anaphylactic reaction hypersensitivity natural recombinant interferonbeta , human albumin , proteins derive CHO cells/formulation . 19 . History depression psychotic feature , require ECT hospitalization , accompany suicidal ideation , gesture , attempt . 20 . History seizure , except isolate febrile seizure childhood .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Lymphocyte</keyword>
	<keyword>Monocyte</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Th2</keyword>
	<keyword>Colonoscopy</keyword>
	<keyword>Ulcerative Colitis</keyword>
</DOC>